Departed
Richard C. Straube
Consulting Chief Medical Officer
SNGX ·
SOLIGENIX, INC.
Dr. Straube ceased serving as the Company's Consulting Chief Medical Officer.
Ready 8-Ks
50
Latest filing
June 26, 2026, 4:06 PM ET
Top materiality
0.90
Event mix
other_material ×22 · regulatory ×17 · other ×5
Sentiment
16 pos · 13 neg · 21 neu
Executive change
recent →
Recent 8-K filings for SNGX
Highest-materiality recent filing
Soligenix Phase 3 FLASH2 trial of HyBryte for CTCL halted for futility
- Data Monitoring Committee interim efficacy analysis recommended halt; HyBryte failed to show benefit at 18 weeks.
- Company reports ~$5.9M cash; evaluating strategic options including M&A or advancing dusquetide for Behçet's Disease.
-
Received Nasdaq notice for non-compliance with $1.00 minimum bid price; 180 days until Dec 7, 2026 to regain compliance.
-
Soligenix Phase 3 FLASH2 trial of HyBryte for CTCL halted for futility
Data Monitoring Committee interim efficacy analysis recommended halt; HyBryte failed to show benefit at 18 weeks.
-
Soligenix provides pipeline update; FLASH 2 interim analysis in 2Q, cash through 2026
66 patients enrolled in confirmatory Phase 3 FLASH 2 trial for HyBryte in CTCL as of Feb 10; interim analysis expected 2Q 2026.
-
Soligenix enters ATM equity facility with Rodman & Renshaw for up to $3.45M
Up to $3,450,000 of common stock may be sold at market prices through Rodman & Renshaw as sales agent.
-
Soligenix regains Nasdaq minimum stockholders' equity compliance
Received Nasdaq letter on Nov 18, 2025 confirming compliance with minimum $2.5M stockholders' equity requirement.
-
Soligenix closes $7.5M public offering; cash runway extended through 2026
Gross proceeds of ~$7.5M from sale of 5,555,560 units at $1.35/unit, each consisting of one share (or pre-funded warrant) and one warrant.
-
FDA grants Soligenix orphan drug designation for SGX945 in Behçet's Disease
FDA orphan drug designation for dusquetide (SGX945) in Behçet's Disease based on Phase 2a results showing biological efficacy and safety.
-
Soligenix receives Nasdaq deficiency notice for stockholders' equity below $2.5M
Stockholders' equity of $1,828,951 as of June 30, 2025, below Nasdaq's $2.5M minimum.
-
Soligenix SGX945 Phase 2a: 40% improvement in Behçet's ulcers, matching Otezla's 37%
SGX945 achieved 40% improvement vs placebo on primary endpoint at Week 4; apremilast (Otezla) had 37% improvement.
-
Soligenix repays $10M Pontifax loan early, terminates Loan and Security Agreement
Repaid all outstanding obligations under the December 2020 Loan Agreement with Pontifax Medison Finance.
-
Soligenix amends loan deal with Pontifax; conversion price cut to $3.81/$4.23
Conversion price reduced to $3.81 for first 501,648 shares issued after Oct 7, 2024, then $4.23 for subsequent shares.
-
Soligenix enters ATM equity sales agreement for up to $5.8M with AGP
Agreement with A.G.P./Alliance Global Partners allows sale of up to $5.8M in common stock at market prices from time to time.
-
Soligenix regains Nasdaq compliance after reverse stock split, delisting threat resolved
Received Nasdaq letter on July 24, 2024 confirming regained compliance with Minimum Bid Price Rule.
-
Soligenix induces warrant exercise for up to $4.2M, issues new warrants at 150% coverage
Up to 703,125 existing warrants exercised at $6.00/share; gross proceeds up to ~$4.2M.
-
Soligenix to effect 1-for-16 reverse stock split effective June 5, 2024
Reverse stock split at 1-for-16 ratio; effective 4:00 p.m. EST June 5, 2024.
-
Soligenix prices $4.75M public offering of common stock and warrants
Gross proceeds ~$4.75M from unit offering: one share (or pre-funded warrant) and one common warrant per unit.
-
Soligenix gets EMA agreement on confirmatory Phase 3 design for HyBryte in CTCL
EMA agreed on key design for FLASH2: double-blind, placebo-controlled, 18-week continuous treatment.
-
Soligenix receives Nasdaq delisting notice; common stock may be suspended
Nasdaq notified Soligenix on Dec 21, 2023, of failure to meet $1.00 minimum bid price rule.
-
Soligenix dismisses auditor EisnerAmper, engages Cherry Bekaert; notes material weakness
Audit committee dismissed EisnerAmper and engaged Cherry Bekaert as new independent auditor for FY 2023.
-
Soligenix receives Nasdaq bid price deficiency notice; 180 days to regain compliance
Received Nasdaq notice on June 23, 2023 for failing $1.00 minimum bid price for 30 consecutive business days.
-
Soligenix regains Nasdaq compliance; Panel Monitor imposed for one year
Received Nasdaq letter on May 23, 2023 confirming regained compliance with Shareholders' Equity Requirement.
-
Soligenix closes $8.5M public offering of common stock and warrants
Public offering of 6,538,500 units (common stock or pre-funded warrants plus common warrants) at $1.30/unit.
-
Soligenix obtains exclusive option for Phase 2/3-ready topical Pentoxifylline in Behçet's Disease
Exclusive option agreement with Silk Road Therapeutics to acquire topical Pentoxifylline for mucocutaneous ulcers in Behçet's Disease.
-
Soligenix amends loan with Pontifax; repays $5M; reduces minimum cash covenant to $1.5M
Repaid $5M of $8M loan principal, leaving $3M outstanding; prepayment premium eliminated.
-
Soligenix says FDA requires second Phase 3 study for HyBryte NDA after Type A meeting
FDA refused to file NDA for HyBryte (CTCL); requires positive results from a second clinical study.
-
Soligenix gets Nasdaq extension to May 15, 2023 for equity listing compliance
Nasdaq extended the deadline to regain Shareholders' Equity Requirement compliance from March 31, 2023 to May 15, 2023.
-
Nasdaq granted continued listing conditional on meeting minimum bid price by Feb 24 and stockholders' equity by March 31, 2023.
-
Soligenix receives FDA Refusal to File for HyBryte NDA in CTCL
FDA issued Refusal to File (RTF) letter for HyBryte NDA for early-stage cutaneous T-cell lymphoma.
-
Soligenix to effect 1-for-15 reverse stock split, effective Feb 9, 2023
Stockholders approved reverse split (range 1:2 to 1:20) at Feb 8 special meeting; board set ratio at 1:15.
-
Record date Jan 3, 2023; distribution Jan 4, 2023; each common share gets 1/1000th of Series D.
-
Soligenix receives Nasdaq delisting notice for failure to meet $1.00 bid price rule
Nasdaq notified Soligenix on Dec 20, 2022 that it failed to regain compliance with the Minimum Bid Price Rule by the Dec 19, 2022 deadline.
-
Soligenix submits NDA to FDA for HyBryte in cutaneous T-cell lymphoma; targets H2 2023 approval
NDA submitted for HyBryte (synthetic hypericin) to treat early stage CTCL, a rare cancer affecting >25,000 US patients.
-
Soligenix receives Nasdaq non-compliance notice for equity deficiency; share increase vote fails
Stockholders' equity of $1,032,002 reported for Q3 2022 falls below Nasdaq's $2.5M minimum.
-
Soligenix invited by BARDA to submit $25M contract proposal for Ebola/Marburg vaccines
BARDA invites Soligenix to submit full contract proposal for SuVax and MarVax vaccines.
-
Soligenix forms Psoriasis Medical Advisory Board; Phase 2a study starts December 2022
Formed Medical Advisory Board (MAB) for SGX302 (synthetic hypericin) in mild-to-moderate psoriasis.
Executive changes
Role change
Christopher Pullion
Medical Director
SNGX ·
SOLIGENIX, INC.
Dr. Straube's responsibilities will be transitioned to Dr. Christopher Pullion, the Company's Medical Director.
Departed
Timothy R. Coté
member of the Board of Directors
SNGX ·
SOLIGENIX, INC.
On July 7, 2023, Timothy R. Coté resigned, for personal reasons, as a member of the Board of Directors of Soligenix, Inc.
Appointed
Timothy R. Coté
director
SNGX ·
SOLIGENIX, INC.
On May 3, 2023, the Board of Directors (the “Board”) of Soligenix, Inc. (the “Company”) increased the size of the Board from five to six members and appointed Timothy R. Coté, MD, MPH as a director, with an initial term expiring at the Company’s 2023 Annual Meeting of Stockholders.
Materiality & sentiment trend
Max materiality 0.90 · Median 0.65 · Most common event other_material